FIELD: medicine.
SUBSTANCE: group of inventions relates to pharmacy and medicine. Disclosed is the use of a complex of hydroxypropyl-β-cyclodextrin (GPβCD) with progesterone or with testosterone at a molar ratio of 2:1 to 2.2:1, wherein GPβCD contains less than 0.3% by weight of unsubstituted β-cyclodextrin, for the preparation of a medicament (particularly in the form of a solution) for oral administration for the treatment of a disease requiring treatment with progesterone or testosterone; a pharmaceutical composition for the same purpose and a corresponding method of treatment.
EFFECT: technical result: the claimed mole ratio of GPβCD to hormones ensures high content thereof in blood plasma after ingestion by optimising their solubility, penetrating power and metabolic stability; the claimed composition provides effective plasma concentrations following oral administration of low doses of progesterone or testosterone as compared to oral compositions currently available on the market, which provides higher safety and better compliance with patient regimens.
21 cl, 10 dwg, 8 tbl
